131 related articles for article (PubMed ID: 38294959)
1. Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
Iocolano M; Yegya-Raman N; Friedes C; Wang X; Kegelman T; Lee SH; Duan L; Li B; Levin WP; Cengel KA; Konski A; Langer CJ; Cohen RB; Sun L; Aggarwal C; Doucette A; Xiao Y; Kevin Teo BK; O'Reilly S; Zou W; Bradley JD; Simone CB; Feigenberg SJ
Cancer; 2024 Jun; 130(11):2031-2041. PubMed ID: 38294959
[TBL] [Abstract][Full Text] [Related]
2. First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.
Remick JS; Schonewolf C; Gabriel P; Doucette A; Levin WP; Kucharczuk JC; Singhal S; Pechet TTV; Rengan R; Simone CB; Berman AT
Clin Lung Cancer; 2017 Jul; 18(4):364-371. PubMed ID: 28162946
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
4. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy.
Kim N; Myoung Noh J; Lee W; Park B; Park H; Young Park J; Pyo H
Radiother Oncol; 2021 Mar; 156():166-173. PubMed ID: 33359267
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
6. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
Liao Z; Lee JJ; Komaki R; Gomez DR; O'Reilly MS; Fossella FV; Blumenschein GR; Heymach JV; Vaporciyan AA; Swisher SG; Allen PK; Choi NC; DeLaney TF; Hahn SM; Cox JD; Lu CS; Mohan R
J Clin Oncol; 2018 Jun; 36(18):1813-1822. PubMed ID: 29293386
[TBL] [Abstract][Full Text] [Related]
7. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
Shiraishi Y; Fang P; Xu C; Song J; Krishnan S; Koay EJ; Mehran RJ; Hofstetter WL; Blum-Murphy M; Ajani JA; Komaki R; Minsky B; Mohan R; Hsu CC; Hobbs BP; Lin SH
Radiother Oncol; 2018 Jul; 128(1):154-160. PubMed ID: 29248170
[TBL] [Abstract][Full Text] [Related]
8. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
9. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer.
Gomez DR; Tucker SL; Martel MK; Mohan R; Balter PA; Lopez Guerra JL; Liu H; Komaki R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1010-6. PubMed ID: 22920974
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.
Ling DC; Hess CB; Chen AM; Daly ME
Clin Lung Cancer; 2016 Jan; 17(1):18-23. PubMed ID: 26303127
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma.
Hirano Y; Onozawa M; Hojo H; Motegi A; Zenda S; Hotta K; Moriya S; Tachibana H; Nakamura N; Kojima T; Akimoto T
Radiat Oncol; 2018 Feb; 13(1):23. PubMed ID: 29426342
[TBL] [Abstract][Full Text] [Related]
12. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
13. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.
Wang XS; Shi Q; Williams LA; Komaki R; Gomez DR; Lin SH; Chang JY; O'Reilly MS; Bokhari RH; Cox JD; Mohan R; Cleeland CS; Liao Z
J Pain Symptom Manage; 2016 May; 51(5):832-8. PubMed ID: 26891607
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
Shiraishi Y; Xu C; Yang J; Komaki R; Lin SH
Radiother Oncol; 2017 Oct; 125(1):48-54. PubMed ID: 28917586
[TBL] [Abstract][Full Text] [Related]
15. Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Cortiula F; Hendriks LEL; Wijsman R; Houben R; Steens M; Debakker S; Canters R; Trovò M; Sijtsema NM; Niezink AGH; Unipan M; Urban S; Michelotti A; Dursun S; Bootsma G; Hattu D; Nuyttens JJ; Moretti E; Taasti VT; De Ruysscher D
Radiother Oncol; 2024 Jan; 190():110019. PubMed ID: 38000689
[TBL] [Abstract][Full Text] [Related]
16. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy.
Masuo M; Shinohara E; Kitano M; Maruta R; Chonabayashi S; Endo S; Matumoto S; Nishiyama N; Machitori Y; Kobayashi M
Jpn J Clin Oncol; 2024 Mar; 54(3):312-318. PubMed ID: 38010609
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Sep; 62(5):894-900. PubMed ID: 34260719
[TBL] [Abstract][Full Text] [Related]
20. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer.
Boyce-Fappiano D; Nguyen QN; Chapman BV; Allen PK; Gjyshi O; Pezzi TA; De B; Gomez D; Lin SH; Chang JY; Liao Z; Lee P; Gandhi SJ
Clin Lung Cancer; 2021 Sep; 22(5):e745-e755. PubMed ID: 33707003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
